Peptides for Testosterone: The HPG Axis Compounds

The compounds marketed for testosterone act at four different points of a single feedback loop. Understanding which point is the difference between compounds that are not remotely interchangeable, despite being sold as alternatives to one another.

The axis, briefly

Testosterone production runs through a three-level cascade with feedback at every level:

1. Hypothalamus releases GnRH in pulses.

2. Pituitary responds with LH and FSH.

3. Testes respond to LH by producing testosterone.

4. Testosterone and oestradiol feed back on the hypothalamus and pituitary, suppressing further GnRH and LH release.

That last step is why exogenous testosterone shuts down endogenous production. It is also why every compound below exists — each is an attempt to raise testosterone without triggering that shutdown.

Where each compound acts

Kisspeptin-10

Kisspeptin sits upstream of GnRH — it is the signal that drives GnRH neurons. That position is what makes it interesting: acting above the hypothalamus means the downstream pulsatility is generated by the body rather than imposed.

A 2026 European Journal of Endocrinology study found that chronic subcutaneous kisspeptin-10 stimulated gonadotropin secretion over twelve days in healthy men — notable because sustained stimulation without desensitisation is precisely the problem that limits GnRH agonists.

See the kisspeptin-10 guide.

Gonadorelin

Gonadorelin is GnRH itself. Because native GnRH has a very short half-life and the pituitary responds to pulses rather than to continuous exposure, timing and frequency dominate its behaviour.

The pulsatile-versus-continuous distinction is not a detail. The same molecule stimulates the axis when given in pulses and suppresses it when given continuously. This is a compound where administration pattern determines the direction of the effect.

See the gonadorelin guide.

Enclomiphene

Enclomiphene blocks oestrogen receptors at the hypothalamus and pituitary. Since oestradiol is a major part of the negative feedback signal, blocking it makes the brain read testosterone as lower than it is and increase LH output.

A 2025 meta-analysis of randomised controlled trials examined clomiphene and enclomiphene for male hypogonadism — genuine randomised human evidence, which distinguishes this from most compounds in the category.

It is also not approved as a standalone product despite that evidence base. See the enclomiphene guide.

Why the point of action matters

What bloodwork establishes

1. Whether testosterone is genuinely low, measured properly — morning, fasted, repeated.

2. Whether LH and FSH are high or low, which distinguishes primary from secondary hypogonadism and determines everything else.

3. Oestradiol and SHBG, which change how a total testosterone figure should be read.

4. Prolactin, since elevation has specific causes requiring specific investigation.

5. Whether symptoms match the numbers, because frequently they do not.

None of these compounds is a substitute for that workup, and all of them are more sensible after it. Fatigue, low libido and poor recovery have many causes, most of which are not testosterone.

See also the peptides for men guide.